trimetazidine

Trimetazidine, an anti-ischemic (anti-anginal) metabolic agent, could improve myocardial glucose utilization through inhibition of long-chain 3-ketoacyl CoA thiolase activity and results in a reduction in fatty acid oxidation and a stimulation of glucose

Trimetazidine dihydrochloride (Vastarel F) can improve myocardial glucose utilization by inhibiting fatty acid metabolism. Trimetazidine is the first cytoprotective anti-ischemic agent, also used as a vasodilator in ischemic heart disease or angina.

TriMetazidine EP Impurity-D is the starting material for the synthesis of TriMetazidine and an intermediate for the synthesis of various compounds.

Trimetazidine-N-oxide, the major active metabolite of Trimetazidine, is a selective long-chain inhibitor of 3-ketoyl coenzyme A thiolase (IC50: 75 nM) with anti-oxidant, anti-inflammatory, antinociceptive, and gastroprotective properties.

Trimetazidine-d8 Dihydrochloride is a deuterated compound of Trimetazidine Dihydrochloride. Trimetazidine Dihydrochloride has a CAS number of 13171-25-0. Trimetazidine dihydrochloride can improve myocardial glucose utilization by inhibiting fatty acid metabolism. Trimetazidine is the first cytoprotective anti-ischemic agent, also used as a vasodilator in ischemic heart disease or angina.